New treatment stragies in metastatic castration resistant prostate cancer: Re-Docetaxel, Abiraterone asetate, Cabazitaxel, MDV 3100

  • Sıtkı Ün
  • Ferruh Zorlu

Bull Urooncol 2012;11(2):159-163

Treatment of metastatic castration resistant prostate cancer after progression from Docetaxel chemoterapy nowadays have many alternatives. Re-tereatment with docetaxel have shown PSA response but most of the studies are retrospective and non randomised. Abiraterone acetate and recently MDV3100 as an oral antiandrogen agent have shown significant survival advantage without major toxicity and stays as a main drug. Cabazitaxel in combination with prednisone is the only chemoterapic agent to have shown significant survival benefit but have a toxicity problems. İn this review we summarize the current evidence.

Keywords: Castration Resistat Prostate Cancer, post Docetaxel, Abireterone acetate, Cabazitaxel